MX2020001422A - Metodos para el tratamiento de hcv. - Google Patents

Metodos para el tratamiento de hcv.

Info

Publication number
MX2020001422A
MX2020001422A MX2020001422A MX2020001422A MX2020001422A MX 2020001422 A MX2020001422 A MX 2020001422A MX 2020001422 A MX2020001422 A MX 2020001422A MX 2020001422 A MX2020001422 A MX 2020001422A MX 2020001422 A MX2020001422 A MX 2020001422A
Authority
MX
Mexico
Prior art keywords
treatment
methods
weeks
compound
pharmaceutically acceptable
Prior art date
Application number
MX2020001422A
Other languages
English (en)
Inventor
Matthew Kosloski
Bo Fu
Christine Collins
Abhishek Gulati
Jens Kort
Yang Lei
Chih - Wei Lin
Ran Liu
Federico Mensa
Iok Chan Ng
Tami Pilot-Matias
David Pugatch
Nancy S Shulman
Roger Trinh
Rolando M Viani
Stanley Wang
Zhenzhen Zhang
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/667,212 external-priority patent/US20200368229A9/en
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2020001422A publication Critical patent/MX2020001422A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La presente invención presenta tratamientos sin interferón para el tratamiento de HCV. Preferentemente, el tratamiento tiene una duración de tratamiento más corta, tal como de no más de 12 semanas. En un aspecto, el tratamiento comprende administrar al menos dos agentes antivirales de acción directa a un sujeto con infección por HCV, en donde el tratamiento dura 12 semanas y no incluye la administración de interferón o ribavirina, y dichos al menos dos agentes antivirales de acción directa comprenden (a) el Compuesto 1 o una sal aceptable desde el punto de vista farmacéutico de este y (b) el Compuesto 2 o una sal aceptable desde el punto de vista farmacéutico de este.
MX2020001422A 2017-08-02 2018-07-20 Metodos para el tratamiento de hcv. MX2020001422A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/667,212 US20200368229A9 (en) 2013-03-14 2017-08-02 Methods for Treating HCV
PCT/US2018/042992 WO2019027694A1 (en) 2017-08-02 2018-07-20 METHODS OF TREATING HCV

Publications (1)

Publication Number Publication Date
MX2020001422A true MX2020001422A (es) 2020-08-06

Family

ID=60190576

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020001422A MX2020001422A (es) 2017-08-02 2018-07-20 Metodos para el tratamiento de hcv.

Country Status (15)

Country Link
US (1) US20200222397A1 (es)
EP (1) EP3437643A1 (es)
JP (1) JP2019026633A (es)
KR (1) KR20200047552A (es)
CN (1) CN111163779A (es)
AU (2) AU2017248487A1 (es)
BR (2) BR102017022849A8 (es)
CA (2) CA2981993A1 (es)
EA (1) EA202090412A1 (es)
IL (1) IL272420A (es)
MX (1) MX2020001422A (es)
SG (1) SG11202000948QA (es)
TW (1) TW201909897A (es)
WO (1) WO2019027694A1 (es)
ZA (1) ZA202000943B (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
BR112013006693B1 (pt) * 2010-09-21 2022-07-12 Enanta Pharmaceuticals, Inc Compostos inibidores da serino protease hcv derivada de prolina macrocíclica
CH707030B1 (de) 2011-10-21 2015-03-13 Abbvie Inc Kombinationsbehandlung von DAAs zur Verwendung in der Behandlung von HCV
WO2014099908A1 (en) * 2012-12-17 2014-06-26 Genentech, Inc. Methods for inhibiting viral infection in transplant patients
HUE036069T2 (hu) * 2013-03-14 2018-06-28 Abbvie Inc Közvetlenül ható vírusellenes szerek és ribavirin kombinációja HCV-betegek kezelésére
EP3213750B1 (en) * 2013-03-14 2020-08-12 AbbVie Inc. Combination of two antivirals for treating hepatitis c
MX2016012722A (es) * 2014-04-02 2016-12-16 Abbvie Inc Metodos para tratar el virus de la hepatitis c.
CN112704726A (zh) * 2014-04-02 2021-04-27 艾伯维公司 治疗hcv的方法
BR112018000383A2 (pt) * 2015-07-08 2018-09-18 Abbvie Inc métodos para tratar hcv

Also Published As

Publication number Publication date
SG11202000948QA (en) 2020-02-27
CA3072026A1 (en) 2019-02-07
CN111163779A (zh) 2020-05-15
BR102017022849A8 (pt) 2022-09-20
WO2019027694A1 (en) 2019-02-07
ZA202000943B (en) 2022-10-26
US20200222397A1 (en) 2020-07-16
EA202090412A1 (ru) 2020-05-27
TW201909897A (zh) 2019-03-16
AU2017248487A1 (en) 2019-02-21
BR102017022849A2 (pt) 2019-03-19
KR20200047552A (ko) 2020-05-07
BR112020002308A2 (pt) 2020-08-04
CA2981993A1 (en) 2019-02-02
EP3437643A1 (en) 2019-02-06
IL272420A (en) 2020-03-31
AU2018311684A1 (en) 2020-02-27
JP2019026633A (ja) 2019-02-21

Similar Documents

Publication Publication Date Title
MX2016012799A (es) Metodos para tratar el virus de la hepatitis c.
MX2020005054A (es) Combinacion de dos agentes antivirales para el tratamiento de hepatitis c.
MX2015012536A (es) Combinacion de agentes antivirales de accion directa y ribavirina para el tratamiento de pacientes con vhc.
MX2018000240A (es) Metodos para tratar el vhc.
PH12018550150A1 (en) Elimination of hepatitis b virus with antiviral agents
PH12018550201A1 (en) Hepatitis b antiviral agents
PH12014502848A1 (en) Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon
GB2506085A (en) Combination treatment (eg with ABT-072 or ABT-333) of DAAS for use in treating HCV
PH12020550065A1 (en) Hepatitis b antiviral agents
MX2019012884A (es) Terapia de combinacion.
MX2016012722A (es) Metodos para tratar el virus de la hepatitis c.
RU2015114543A (ru) Способы лечения гепатита с
MX2021002147A (es) Tratamiento de la infección por virus de la hepatitis delta con interferón lambda.
PH12021550632A1 (en) Monomer and multimeric anti-hbv agents
MX2022006742A (es) Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter.
MX2022007911A (es) Procedimiento de tratamiento de una infeccion virica usando un agonista de tlr7.
WO2016090107A3 (en) Treatment of hepatitis delta virus infection
RU2015114566A (ru) Способы лечения гепатита с
MX2020001422A (es) Metodos para el tratamiento de hcv.
MX2018001905A (es) Metodos para el tratamiento del virus de hepatitis c (vhc).
AU2019384793A8 (en) Methods for treating acute HCV
NZ631789A (en) Combination of direct acting antiviral agents and ribavirin for treating hcv patients
EA201892004A1 (ru) Противовирусные средства для лечения гепатита b
UA101772U (uk) Спосіб лікування хронічного вірусного гепатиту с із супутньою неалкогольною жировою хворобою печінки
RU2008142658A (ru) Способ лечения инфекционных поражений нервной системы